Difficulty: Medium
Average Score: 85%
Practice
An 83-year-old woman with Parkinson's disease is currently being treated with carbidopa/levodopa, but her Parkinson's symptoms are worsening. She has normal liver function and no history of liver disease. Selegiline is added to her regimen. How does selegiline help in Parkinson's disease?
Correct answer
C
Rationale
In the context of treating Parkinson's disease, the addition of selegiline to the regimen of an 83-year-old woman who is already on carbidopa/levodopa aims to improve symptom management. The correct answer is C) Inhibition of MAO.
Selegiline is a monoamine oxidase (MAO) inhibitor, specifically targeting MAO-B. MAO-B breaks down dopamine in the brain, and by inhibiting this enzyme, selegiline helps to increase dopamine levels in the brain. This increase in dopamine levels can alleviate the symptoms of Parkinson's disease, such as tremors and muscle rigidity.
Now, let's look at why the other options are incorrect:
A) Increased norepinephrine synthesis: This is not the mechanism of action of selegiline in treating Parkinson's disease. Norepinephrine is not the primary neurotransmitter affected in Parkinson's.
B) Inhibition of COMT: Selegiline does not inhibit catechol-O-methyltransferase (COMT), which is another enzyme involved in dopamine metabolism.
D) Stimulation of acetylcholine release: While acetylcholine is involved in Parkinson's disease, selegiline does not directly stimulate its release.
Understanding the mechanisms of action of different drugs used in treating Parkinson's disease is crucial for healthcare professionals to make informed decisions about patient care. By grasping how each drug works, they can optimize treatment plans and improve patient outcomes.
Selegiline is a monoamine oxidase (MAO) inhibitor, specifically targeting MAO-B. MAO-B breaks down dopamine in the brain, and by inhibiting this enzyme, selegiline helps to increase dopamine levels in the brain. This increase in dopamine levels can alleviate the symptoms of Parkinson's disease, such as tremors and muscle rigidity.
Now, let's look at why the other options are incorrect:
A) Increased norepinephrine synthesis: This is not the mechanism of action of selegiline in treating Parkinson's disease. Norepinephrine is not the primary neurotransmitter affected in Parkinson's.
B) Inhibition of COMT: Selegiline does not inhibit catechol-O-methyltransferase (COMT), which is another enzyme involved in dopamine metabolism.
D) Stimulation of acetylcholine release: While acetylcholine is involved in Parkinson's disease, selegiline does not directly stimulate its release.
Understanding the mechanisms of action of different drugs used in treating Parkinson's disease is crucial for healthcare professionals to make informed decisions about patient care. By grasping how each drug works, they can optimize treatment plans and improve patient outcomes.